MED12 and non-small cell lung carcinoma: Despite the limited number of MED12-mutated samples (only three samples were identified as the MED12-mut samples in both Naiyer2015), MED12-mutated NSCLC samples showed a significantly prolonged survival period compared to the wild-type group (Fig. 1c, Table S1), consistent with the MSKCC dataset.